# Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

> **NCT00003631** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 118 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** carboplatin
- **DRUG:** carmustine
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **DRUG:** melphalan
- **PROCEDURE:** bone marrow ablation with stem cell support
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00003631
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2016-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003631, "Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*